Asset
Direclidine
Neurocrine Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07288320 | phase2 | recruiting | 2025-12-24 | 2028-02-01 | Neurocrine Biosciences | An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania |
| NCT07227818 | phase3 | recruiting | 2025-12-16 | 2029-07-01 | Neurocrine Biosciences | Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia |
| NCT05545111 | phase2 | completed | 2022-10-04 | 2024-07-10 | Neurocrine Biosciences | Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia |
| NCT06963034 | phase3 | recruiting | 2025-05-08 | 2027-10-01 | Neurocrine Biosciences | NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia |
| NCT07105098 | phase3 | recruiting | 2025-08-11 | 2027-11-01 | Neurocrine Biosciences | NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia |
FDA applications (0)
This company has no applications containing this asset.